Ace Therapeutics, a preclinical contract research organization based in New York, has announced a comprehensive suite of analgesic drug development services that covers the entire pipeline from early target discovery to safety assessment. The company's integrated platform features a wide array of validated in vivo pain models and systematic preclinical assessment tools aimed at advancing pain therapeutics for pharmaceutical and biotechnology clients worldwide.
The core of Ace Therapeutics' offering is its extensive portfolio of standardized and customized in vivo pain models for drug testing, spanning nearly all mainstream pain classifications. These include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models. To complement these models, the company provides systematic preclinical pain assessment services using well-established methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test for mechanical, thermal, chemical, cold, and electrical pain assessment.
In addition to in vivo systems, Ace Therapeutics has developed in vitro neuropathic pain model services leveraging dorsal root ganglion cells, iPSC-derived sensory neurons, and co-culture systems to explore pain-related cellular mechanisms. This dual approach enhances translational value by bridging cellular insights with whole-organism responses. The company's services extend to target-based and modality-based drug discovery, supporting research on G-protein coupled receptors, cytokine networks, and ion channels including voltage-gated channels. It offers professional solutions for small-molecule analgesics, biologics such as antibodies and recombinant proteins, peptides, cell therapies, and gene therapy candidates.
Mechanism-driven research covers peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways. The full-service pipeline also includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection. For special research needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms and research objectives.
The announcement is significant as it addresses the complex demands of modern pain drug research, a field with high unmet needs due to the opioid crisis and limited effective treatments for chronic pain. By providing a comprehensive, one-stop platform, Ace Therapeutics aims to streamline the development of novel analgesic drugs, potentially bringing safer and more effective pain therapies to market faster. The company's focus on validated models and regulatory-compliant methodologies underscores its commitment to scientific rigor, which is critical for translating preclinical findings into clinical success.
